Optimise viewing for

Toggle between patient and health professional views. The patient version is simplified to help people easily find suitable trials, while the professional view provides full detail.

RecruitingLast updated: 9 October 2025

SuperQol: This study is recruiting people with a new primary diagnosis of pancreatic cancer to see whether intensive nutrition support via telehealth can improve quality of lifeAssessing the impact of an intensive dietitian-led telehealth intervention focusing on nutritional adequacy and symptom control, on quality of life in patients with pancreatic cancer: a randomised controlled trial

Trial purpose

Medical clipboardSide effect and wellbeing

Tumor type

Upper gastrointestinal tract Cancers Upper gastrointestinal tract

Age

People18+

Trial acronym

SuperQol

Clinical summary

Summary

Can dietitian-led intensive telehealth support to maximise nutritional intake through dietary strategies, symptom management and the option for 'top-up' small bowel tube feeding improve quality of life in people with pancreatic cancer?

You may be eligible for this study if you have a new primary diagnosis of borderline resectable, locally advanced, metastatic or inoperable pancreatic cancer and are commencing chemotherapy.

Eligible participants will be randomly (by chance) allocated to one of two groups:

  • usual care or
  • intensive dietetics intervention (counselling, education, symptom management, oral nutrition support, with or without jejunal tube feeding if the participating chooses) delivered via telehealth.

For those randomised to the intervention group, participants will receive the active intervention for 6 months, beginning as soon as possible after diagnosis. Personalised nutrition support and/or advice will be provided. Outcomes will be measured at baseline and at follow up at 3 and 6 months.

It is hoped this study will demonstrate the effectiveness of early and frequent dietetic intervention and supplemental jejunal feeding (when required), in enhancing quality of life. 

Conditions

This trial is treating people with newly diagnosed, borderline resectable, locally advanced, or metastatic pancreatic cancer who are commencing chemotherapy

Eligibility

Inclusion

 

1. At least 18 years of age at time of screening
2. Ability to provide informed consent and willing to comply with study procedures (i.e. completion of study outcome questionnaires, participation in intervention if randomised to intervention group)
3. New diagnosis of borderline resectable, locally advanced or metastatic pancreatic cancer commencing chemotherapy
4. Life expectancy of at least 6 months from the time of screening as judged by the patient's health care team
5. ECOG performance status score of less than or equal to 2.

Exclusion

 

1. Patients with neuroendocrine pancreatic cancers
2. Patients who have previously had a pancreatic cancer surgical resection
3. Patients who have received 2 or more cycles of chemotherapy for PC
4. Patients with serious medical or psychiatric conditions that might compromise protocol-based management as judged by the patient's treating healthcare team
5. Patients receiving ‘end of life’ care
6. Patients who declined or are deemed unsuitable for systemic chemotherapy
7. Patients with insufficient cognition to provide consent as judged by the patient's treating healthcare team
8. Patients with insufficient knowledge of the English language who do not have a family member that can assist with English translation to facilitate completion of outcome data collection, or interviews with the study dietitian

Inclusion

  • Your cancer has spread to other parts of the body (metastatic) or has grown into nearby parts of the body (locally advanced).
  • Your cancer has not spread to other parts of the body, but it is not possible to perform surgery to remove it (unresectable).

Exclusion

  • You have certain types of non-cancer medical conditions.
  • You have had certain treatments, surgical procedures or drugs.
Message

Clinical trials have complex eligibility criteria, and other criteria may apply for this trial. Ask your doctor about whether this trial could be right for you.

Participating hospitals

Recruiting hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

More information

Trial Identifiers

Information on this page is partially produced from ANZCTR *. View further details about this trial on the registry via the links below:

Trial sponsor

Monash University

Scientific Title

Assessing the impact of an intensive dietitian-led telehealth intervention focusing on nutritional adequacy and symptom control, on quality of life in patients with pancreatic cancer: a randomised controlled trial

Get Support

Peer Connect

You might find it helpful to speak to someone who has 'been there before'. Our Peer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.

Know more about Peer Connect

Contact cancer support

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council to speak with an experienced health professional on 13 11 20.

Get support

Multilingual information

Learn more about clinical trials through this collection of resources in languages other than English.

View information